Blockchain technology is rapidly being integrated into many industries across multiple roles, in some cases, revolutionizing processes and clarifying legitimate transactions in the supply chain where the pharmaceutical sector is also one of the critical areas that need diligent action.
Recently, the United States Food and Drug Administration (FDA) commissioner indicated the deployment of blockchain tech in an open pilot project towards the advancement in the drug supply chain process for the pharmaceuticals industry. The document published by the official journal of the United States, The Federal Register on Feb 8, 2019.
Blockchain in Supply Chain
FDA has announced the pilot program under the Drug Supply Chain Security Act (DSCSA Pilot Project Program) with an objective to upgrade the electronic and interoperable system for easy and swift traceability of the distributed prescribed drugs in the Federal Republic.
With this new initiative FDA is trying to provide an opportunity to the active industry players such as authorized manufacturers, repackagers, wholesale distributors, and dispensers including other stakeholders to try out robust technologies in the supply chain while enhancing the prevailing old system in distribution chain while keeping a check on counterfeit drugs to ensure accountability in the industry.
Deliberations Started in 2013
It is worth admiring that the DSCSA has started to contemplate and proposed the development in the conventional system way back in Nov 2013 and signed into law for the better safety of the citizens.
According to the document, the participation date set by the FDA has been started from February 8, 2019, and it will continue through March 11, 2019. The platform would be operable from November 27, 2023, as depicted.
On Feb. 7, 2019, Scott Gottlieb, FDA Commissioner stated in the press release:
“We’re invested in exploring new ways to improve traceability, in some cases using the same technologies that can enhance drug supply chain security, like the use of blockchain.”
Contact Details For More Guidelines:
Daniel Bellingham, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-3130, [email protected]